AI Is Reshaping Drug Development Faster Than Many Expected
Artificial intelligence is rapidly moving from experimental projects into mainstream pharmaceutical research and development. During BioSpace’s NextGen 2026 discussion, biotech executives highlighted how AI, advanced analytics and digital technologies are reshaping the way new medicines are discovered and developed. At the same time, they warned that technology alone cannot replace scientific expertise, reliable data and effective regulatory frameworks.
Why Poor Data Could Become AI’s Biggest Risk in Pharma
Despite growing excitement around AI, industry leaders believe data quality remains the most important factor behind successful innovation. Mo Trikha, CEO of Kivu Bioscience, argued that companies should focus on generating meaningful intelligence rather than simply adopting artificial intelligence tools. According to him, strong datasets enable faster and better decisions, which is critical in an industry where patients cannot afford delays. His comments reflect a broader trend across pharmaceutical organizations that increasingly rely on data-driven decision-making to support development programs.
Digital Twins Are Starting to Change How Clinical Trials Are Run
Another major topic was the growing role of digital twin technology in drug development. Trace Neuroscience CEO Eric Green explained that his company is exploring AI-based approaches to analyze large natural-history datasets and improve clinical trial efficiency. The company has also collaborated with Unlearn AI to evaluate digital twin models that could support smarter study designs. These developments show how digital transformation is moving beyond theory and becoming part of real-world pharmaceutical operations.
At the same time, leaders emphasized that these models are increasingly used to simulate patient outcomes, reduce trial costs, and accelerate decision-making, which could significantly reshape how late-stage clinical programs are designed and executed in regulated environments.
Why China’s Biotech Momentum Is Getting Harder to Ignore
The executives also discussed the growing competitive challenge coming from China’s biotechnology sector. Several speakers noted that China has accelerated innovation through regulatory reforms, faster review processes and continued investment in scientific research. Andy Orth, CEO of City Therapeutics, suggested that greater regulatory flexibility could help strengthen the competitiveness of the U.S. biotechnology ecosystem. According to him, scientific innovation alone is not enough. Regulatory efficiency is becoming a critical factor in determining how quickly new therapies reach patients.
Why AI Alone Will Not Define Pharma’s Next Leaders
Despite the excitement surrounding AI, the speakers repeatedly stressed that pharmaceutical companies should avoid chasing technology trends without a clear scientific purpose. While AI can improve efficiency and support decision-making, it cannot replace expertise, critical thinking and rigorous research. The message from NextGen 2026 was clear: AI, digital twins and advanced analytics are transforming pharmaceutical R&D. However, organizations that combine these technologies with trusted data, scientific discipline and effective regulatory strategies will be best positioned to succeed in the next generation of pharmaceutical innovation.
If pharmaceutical companies want to successfully integrate AI, digital twins, and advanced analytics into regulated environments, they must ensure these technologies are properly validated and compliant with GMP requirements.
Through our Qualification and Validation for GMP-Regulated Systems service, we help teams build reliable, inspection-ready digital and AI-enabled systems across the full pharmaceutical lifecycle.
Source: